Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LY-354740 (Eli Lilly).

Andrzej Pilc1

  • 1Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Smetna 12, Poland. nfpilc@cyf-kr.edu.pl

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed
Summary

Lilly is developing LY-354740, a novel metabotropic glutamate receptor group II agonist, for the potential treatment of anxiety. This compound shows promise in addressing anxiety disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clozapine levels in inpatients with schizophrenia are not a predictor of rehospitalization: a naturalistic retrospective study.

Pharmacological reports : PR·2026
Same author

Coadministration of scopolamine and mGlu2 NAM VU6001966 as a novel antidepressant approach: Lowering effective dose and reducing cognitive side effects.

Psychopharmacology·2025
Same author

Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior.

Pharmacology, biochemistry, and behavior·2025
Same author

Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation.

Pharmacological reports : PR·2024
Same author

Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.

Pharmacological reports : PR·2023
Same author

The Potential of Scopolamine as an Antidepressant in Major Depressive Disorder: A Systematic Review of Randomized Controlled Trials.

Biomedicines·2023

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Anxiety disorders represent a significant unmet medical need.
  • Metabotropic glutamate receptors (mGluRs) are implicated in mood regulation.

Purpose of the Study:

  • To investigate LY-354740, a derivative of L-CCG-1, as a potential therapeutic agent for anxiety.
  • To explore the efficacy of metabotropic glutamate receptor group II agonists in treating anxiety.

Main Methods:

  • Development of LY-354740, a novel compound.
  • Preclinical evaluation of LY-354740's pharmacological properties.

Main Results:

  • LY-354740 is the lead compound in a series of metabotropic glutamate receptor group II agonists.
  • The compound is under development for its potential anxiolytic effects.

Conclusions:

  • LY-354740 demonstrates potential as a novel treatment for anxiety.
  • Further research into this class of compounds may yield new therapeutic options for anxiety disorders.

Related Experiment Videos